CLINICAL_TRIALS
trial_result
· 2024-09-27
Clinical Trial Update: Descriptive Observational Study ALK-2016-CPHG
Summary
A descriptive observational study of crizotinib in non-small cell lung cancer with ALK or ROS1 rearrangements has completed, and results were posted on 2024-09-…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: NSCLC, Crizotinib | Status: COMPLETED | Results posted: 2024-09-27